This compound is an active pharmaceutical ingredient impurity associated with alogliptin. It is characterized by a pyrimidinedione core with an aminopiperidine substituent and a benzonitrile group.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Cupric citrate
pharmaceutical raw material
Teflaro
pharmaceutical raw material
(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carbonitrile
pharmaceutical raw material
7-ethyl-10-hydroxycamptothecin
pharmaceutical raw material
(S)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile
pharmaceutical raw material
2-({6-[(3R)-3-Aminopiperidin-1-yl]-3-(²H₃)methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
pharmaceutical intermediate
Alogliptin (13CD3)
pharmaceutical raw material
(S)-Alogliptin Benzoate Salt
pharmaceutical raw material
2-[[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
ZSBOMTDTBDDKMP-UHFFFAOYSA-N
CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
—
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.